Irati
Garmendia Iturbe
Chercheuse jusqu' 2019
Instituto de Salud Carlos III
Madrid, EspañaPublications en collaboration avec des chercheurs de Instituto de Salud Carlos III (2)
2021
-
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3